Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc. - Common Stock
(NQ:
FHTX
)
4.880
+0.020 (+0.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Foghorn Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
April 24, 2023
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Via
Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
↗
April 24, 2023
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P...
Via
Benzinga
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold
↗
April 24, 2023
Via
Benzinga
Expert Ratings for Foghorn Therapeutics
↗
March 28, 2023
Via
Benzinga
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed
↗
March 15, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
October 20, 2022
Thursday saw 177 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 24, 2023
Via
Benzinga
Foghorn Therapeutics Provides an Update on FHD-609
April 24, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
April 10, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
April 06, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
↗
March 28, 2023
Via
Benzinga
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
March 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
↗
February 16, 2023
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
Via
The Motley Fool
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
January 09, 2023
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
December 05, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
↗
January 05, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
November 22, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
November 14, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
November 09, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
November 08, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
October 27, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
October 26, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
October 20, 2022
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
↗
September 30, 2022
Gainers
Via
Benzinga
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
↗
September 27, 2022
Gainers
Via
Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
↗
September 28, 2022
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022
↗
August 24, 2022
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
↗
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.